16 results about "Enterovirus 71" patented technology

The invention provides a mutant of enterovirus 71 and virus-like particles thereof, and relates to the field of biological medicines. The enterovirus 71 type virus-like particle is obtained by modifying structural genes VP0, VP1 and VP3 of virus capsid protein by utilizing computational structure biology and completing self-assembly in vivo through a hansenula polymorpha expression system. Compared with the unmodified enterovirus 71 type mutant and the virus-like particles thereof, the enterovirus 71 type mutant and the virus-like particles thereof have the advantages that the immunogenicity can be obviously improved, and the clinical application prospect is relatively high.

The invention discloses a construction method and application of an enterovirus 71 type susceptible transgenic mouse model, and belongs to the technical field of biology. The method comprises the following steps: up-regulating or enhancing or improving the content or / and activity of placenta specific protein 8 in a receptor mouse to obtain a mouse overexpressing the placenta specific protein 8, hybridizing the mouse overexpressing the placenta specific protein 8 with a wild mouse to obtain an F1-generation heterozygote mouse, a homozygote mouse obtained after the F1-generation heterozygote mice are hybridized with each other is an enterovirus 71 type susceptible transgenic mouse model. The application has the advantages that not only is the susceptibility of mice to EV71 increased, but also a proper animal model is provided for exploring the important function of Plac8 in the EV71 infection process.

The application discloses a high-specificity and high-affinity monoclonal antibody and antigen-binding fragment thereof for recognizing enterovirus 71 capsid protein VP1. The amino acid sequence of the heavy chain variable region of the antibody is shown as SEQ ID NO. 1, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 5. The monoclonal antibody or antigen-binding fragment thereof can be used for qualitative and quantitative detection of enterovirus 71 VP1 protein.

This invention discloses the use of an anthraquinone natural product (Aloesaponarin II) in the treatment of enterovirus 71. Experimental studies of Aloesaponarin II's anti-EV71 activity have shown that Aloesaponarin II inhibits the cytopathic effect (CPE) produced by EV71 on host cell RD, enhances cell survival, and reduces progeny virus production, suggesting its potential application in the preparation of anti-EV71 drugs.

A method of detecting severe disease-associated mutations in an enterovirus 71 (EV-A71), comprising: performing an assay on a test sample containing an EV-A71 genomic RNA, a fragment thereof or an amplicon thereof, or an EV-A71 VP1 protein or fragment thereof to detect one or more severe disease-associated mutations in the EV-A71 genomic RNA, the fragment thereof or the amplicon thereof, or the EV-A71 protein or fragment thereof, wherein the one or more mutations are selected from mutations at positions corresponding to 5′ UTR nucleotide positions C580, A707, and C709 in an EV-A71 5′ UTR nucleic acid sequence and at residues corresponding to A280 and E145 in an EV-A71 VP1 protein sequence.

The application is application of Huoshi Baiyin granules in treating diseases caused by enterovirus, and provides use of Huoshi Baiyin granules in preparing medicines for preventing, relieving and / or treating diseases caused by enterovirus. The inventor finds that Huoshi Baiyin granules have good inhibitory activity on enterovirus such as coxsackievirus A9 and enterovirus 71. Therefore, the technical scheme of the application has important clinical application value for treating diseases caused by enterovirus.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to alkaloid compounds with anti-Enterovirus 71 (EV71) activity and preparation and application thereof. Four novel alkaloid compounds are isolated from branches and leaves of Daphniphyllum calycinum, and the compounds have novel structures. The skeletons of three compounds (compounds 1-3) are rare polycyclic skeletons substituted by cyano groups, and one compound (compound 4) is a rare Daphmanidin type alkaloid. The four alkaloid compounds have significant anti-EV71 virus activity, and have good application prospects in the development of new drugs for preventing and treating infantile hand-foot-mouth disease induced by EV71 virus.

The present invention discloses a combination vaccine for preventing hand, foot and mouth disease, comprising inactivated enterovirus 71 and inactivated coxsackievirus group A type 16. The present invention also discloses a method for preparing the combination vaccine, which exhibits excellent adsorption efficacy and stability. The multiple antigens described above do not interfere with each other's antigenicity or immune effects after immunization, resulting in excellent immunogenicity and safety. The use of the combination vaccine can significantly simplify the vaccination process, improve vaccination efficiency, and reduce costs.

The application relates to the field of microbial technology, in particular to construction and application of a virus strain with mutation of the 75th amino acid of VP1 protein of enterovirus 71. The amino acid sequence of the mutant of VP1 protein of enterovirus 71 is shown in SEQ ID NO. 1. The mutant of VP1 protein and the corresponding coding nucleic acid molecule can make the proliferation ability of enterovirus 71 decrease, but the virulence in mice increases, and can be used for constructing the mutant virus strain of enterovirus 71, and providing effective biological materials for preparing medicines for preventing and treating enterovirus 71 infection and screening and quality control of the medicines.

The invention provides an enterovirus 71 type nucleic acid colloidal gold detection system based on NISDA isothermal amplification and a vacuum cup, and belongs to the technical field of biological detection. The non-enzymatic isothermal strand displacement amplification (NISDA) technology is combined with colloidal gold detection, the dependence of traditional nucleic acid detection on DNA polymerase, helicase and other expensive enzyme preparations is thoroughly abandoned, meanwhile, complex instruments are not needed, isothermal amplification can be achieved only through a vacuum cup, and the detection cost and the operation threshold are remarkably reduced. The amplified product colloidal gold test strip can rapidly complete visual interpretation, and the sensitivity and the specificity both meet clinical requirements. The technology is especially suitable for resource-deficient areas, basic medical institutions and on-site rapid screening scenes, provides an efficient and economic solution for solving the problem of early diagnosis of enterovirus 71 (EV71) globally, and has important public health significance for suppressing hand-foot-and-mouth disease epidemic situation diffusion and reducing severe risks.

The invention discloses a monoclonal antibody for recognizing enterovirus 71 capsid protein VP1 with high specificity and high affinity and an antigen binding fragment of the monoclonal antibody. The amino acid sequence of a heavy chain variable region of the antibody is as shown in SEQ ID NO.1, and the amino acid sequence of a light chain variable region of the antibody is as shown in SEQ ID NO.5. The monoclonal antibody or the antigen binding fragment thereof can be used for qualitative and quantitative detection of the enterovirus 71 type VP1 protein.

The invention discloses an application of masitinib, C22H17N3 and risedronic acid in preparation of a medicine for treating enterovirus infection. The invention discloses masitinib, C22H17N3, risedronic acid or derivatives thereof or pharmaceutically acceptable salts thereof or prodrugs thereof, or any one of the following applications of substances taking masitinib, C22H17N3, risedronic acid or derivatives thereof or pharmaceutically acceptable salts thereof as active ingredients in preparation of drugs for inhibiting enteroviruses; a2) a medicine for preventing and / or treating diseases caused by enterovirus infection; and A3) a medicine for improving symptoms caused by enterovirus infection. On the basis of an enterovirus type 71 and / or coxsackie virus drug screening model, an active drug masitinib capable of resisting enterovirus type 71, coxsackie virus group A type 9 and / or coxsackie virus group B type 3 is screened from listed drugs, and effect verification is carried out on a type 1 poliovirus model and / or an echovirus type 11 model.

The disclosure provides a mutant of enterovirus 71 and a virus-like particle thereof, and relates to the field of biological medicine.The virus-like particle of enterovirus 71 in the disclosure is obtained by modifying the structural genes VP0, VP1 and VP3 of the virus capsid protein by using computational structural biology, and completing self-assembly in vivo by a Hansenula polymorpha expression system.The mutant of enterovirus 71 and the virus-like particle thereof in the disclosure can significantly improve immunogenicity compared with the unmodified one, and have a high clinical application prospect.

The invention belongs to the technical field of antiviral drugs, and relates to preparation of a 2, 4, 5-polysubstituted pyrimidine derivative and application of the 2, 4, 5-polysubstituted pyrimidine derivative in resisting enterovirus 71. The anti-EV71 activity research experiment of the pyrimidine derivative shows that the pyrimidine derivative has certain inhibitory activity on EV71: the pyrimidine derivative inhibits the cytopathic effect (CPE) generated by EV71 on a host cell Vero, enhances the cell survival rate and reduces the progeny virus yield; host cell lesions caused by EV71 infection can be inhibited, and the method mainly acts on a replication and proliferation stage of EV71 in host cells; therefore, the novel pyrimidine derivatives have the potential of preparing the anti-EV71 virus medicine.

The application discloses a new medical application of astragaloside, in particular, a new medical application of astragaloside in enhancing the anti-enterovirus 71 type of curcumin. Researches show that EV71 infection causes the activity of human normal GES-1 cells to decrease, and the use of curcumin in the infected cells needs to reach a certain concentration to show obvious antiviral effect, and the use of astragaloside and curcumin in combination can show better antiviral effect under the use of lower concentration of curcumin, and the role of astragaloside in enhancing the anti-EV71 of curcumin is determined, and a foundation is laid for the combination of astragaloside and curcumin in preventing and treating hand-foot-mouth disease caused by EV71 infection.

The present invention discloses the use of a diterpenoid compound in the treatment of enterovirus 71. Experimental studies on the anti-EV71 activity of atralabdan-type diterpenoid compounds, including atralabdan A, atralabdan B, and atralabdan C, have shown that the compounds inhibit the cytopathic effect (CPE) produced by EV71 on host cell RD, enhance cell survival, and reduce progeny virus production, demonstrating their potential for use in the preparation of anti-EV71 drugs.